Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
102 Results for "
spreadability
" in MedChemExpress (MCE) Product Catalog:
Products (102)
102 Results for "spreadability" in MCE Product Catalog:
Cat. No.: HY-181548
CAS No.: 3123207-48-4
Research Areas:
YL3147 is a ferroptosis inhibitor. YL3147 also acts as a radical-trapping antioxidant that directly prevents the spread of lipid peroxidation and blocks ferroptosis. YL3147 exerts significant cardioprotective effects in mouse cardiomyopathy models. YL3147 can be used in studies related to cardiomyopathy .
Cat. No.: HY-L080
106 compounds
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.
There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.
MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.
Cat. No.: HY-165096
CAS No.: 72269-48-8
Category:
Target:
Cat. No.: HY-P99648A
CAS No.: 1788032-39-2
Synonyms: BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)
Target:
Research Areas:
Cat. No.: HY-172477
DSPE-PEG5000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelial cells, fibroblasts and smooth muscle cells. DSPE-PEG5000-YIGSR can be used for drug delivery .
Cat. No.: HY-W1135843
CAS No.: 2436472-47-6
Target:
Research Areas:
ARN-75039 is an orally active arenavirus inhibitor. ARN-75039 binds to sites on the GP2 subunit of the mammarenavirus glycoprotein complex, stabilizes prefusion conformation, and blocks viral entry and endosomal membrane fusion to inhibit viral replication and spread. ARN-75039 can be used for the research of lassa fever, arenaviral hemorrhagic fever, and lethal Junín virus infection .
Cat. No.: HY-P990995A
CAS No.: 2690265-18-8
Synonyms: 7G6 Antibody; 7G6-IgG2a
Target:
Research Areas:
Cat. No.: HY-182410
CAS No.: 220669-66-9
Target:
Research Areas:
EGIS-9637 is a non-competitive AMPA antagonist and acylated dihydro-2,3-benzodiazepine class member .
Cat. No.: HY-180785
CAS No.: 932311-85-8
Target:
Research Areas:
G243-1720 is a potent, orally active, broad-spectrum anti-orthopoxvirus agent that functions by targeting the OPG57 (F13) protein and inducing its dimerization. G243-1720 effectively inhibits the replication of various poxviruses, but has no inhibitory effect on non-poxviruses. G243-1720 prevents the formation of extracellular membrane virus particles and the spread between cells. G243-1720 significantly reduces the viral load of monkeypox virus (MPXV) in the lungs of mice
Cat. No.: HY-15150S
Synonyms: R428-d8; BGB324-d8
Cat. No.: HY-W283930
CAS No.: 132858-26-5
Research Areas:
YHV98-4 is a selective, blood-brain barrier-permeable Hv1 inhibitor with an IC50 of 0.7 μM. YHV98-4 reduces ROS production and restores the SHP-1-pAKT signaling pathway. YHV98-4 decreases the spread of hyperphosphorylated Tau protein. YHV98-4 alleviates inflammation and produces analgesic effects. YHV98-4 improves cognitive function in mouse models of Alzheimer's disease. YHV98-4 can be used in research related to inflammatory pain, neuropathic pain and Alzheimer's disease .
Cat. No.: HY-158217B
Synonyms: Gelatin Methacryloyl, 90% methacrylation, Green Fluorescent
Application: cell culture, biological 3D printing, tissue engineering, etc.
Cat. No.: HY-183244
CAS No.: 121412-39-3
Target:
Research Areas:
CGS 21595 is an orally active 5-lipoxygenase inhibitor that blocks the synthesis of 5-hydroxyeicosatetraenoic acid and leukotriene B4. CGS 21595 acts as a prodrug and metabolizes into CGS 19213. CGS 21595 induces lesions in the spinal nerve roots and sciatic nerves of rats, causing mild functional impairments including reduced grip strength, increased spread of the landing feet, and decreased motor activity. CGS 21595 exhibits dose-dependent neurotoxicity in rats, and induces reversible cytoplasmic hyaline droplets in the proximal renal tubules of both male and female rats. CGS 21595 can be used in studies of peripheral toxic neuropathy .
Cat. No.: HY-P5353B
Synonyms: IKVAV sequence TFA; Laminin A-chain fragment TFA
Target:
Research Areas:
Cat. No.: HY-N1393S1
CAS No.: 96739-36-5
Synonyms: NSC 3778-d3; O-Methylsalicylic acid-d3; Salicylic acid methyl ether-d3
Research Areas:
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)-d3 is deuterium-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
Cat. No.: HY-173172
CAS No.: 3076503-34-6
Research Areas:
MG-002 is an orally active eIF4A1 and eIF4A2 inhibitor with a human eIF4A1 IC50 of 43 nM. MG-002 prevents competent ribosome recruitment to mRNA, inhibits cap-dependent mRNA translation, and engages eIF4A2 via the same RNA clamping mechanism to inhibit mRNA translation. MG-002 induces G2/M cell cycle delay, induces apoptosis, suppresses synthesis of c-MYC and cyclin D1, and shows minimal overt toxicity in mice. MG-002 inhibits primary triple-negative breast cancer tumor growth, attenuates metastatic spread, and enhances anti-neoplastic activity of Doxorubicin (HY-15142A) in pre-clinical models .
Cat. No.: HY-181272
MMP-9-IN-14 is a MMP-9 inhibitor (IC50 = 34.46 μM). MMP-9-IN-14 induces G1-phase cell cycle arrest and caspase-dependent apoptosis in cancer cells. MMP-9-IN-14 promotes the accumulation of phosphorylated γH2AX. MMP-9-IN-14 inhibits the migration and invasion of cancer cells, and downregulates the expressions of MMP-2, MMP-9 and hTERT in cancer cells. MMP-9-IN-14 inhibits tumor growth and angiogenic spread in animal models. MMP-9-IN-14 can be used for the research of cancers such as lung adenocarcinoma, cervical cancer and colorectal cancer .
Cat. No.: HY-L025
11,237 compounds
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.
MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.
Cat. No.: HY-P10868A
Synonyms: RLS-0071 TFA
Target:
Research Areas:
Cat. No.: HY-L173
2,967 compounds
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.
MCE designs a unique collection of 2,967 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
